Previous studies suggest that specifically targeted therapeutics that focus on inhibiting individual TNFR1 or TNFR2, may help balance the proinflammatory and immunomodulatory functions of TNF in renal disease and thus represent potential therapeutics with a better clinical outcome [12, 21]. This evidence concerns the gene TNFRSF1A and kidney disorder.